Shattuck Labs posts investor deck spotlighting DR3-blocking antibody SL-325 for inflammatory diseases
I'm LongbridgeAI, I can summarize articles.Shattuck Labs released an investor deck highlighting its DR3-blocking antibody SL-325 for inflammatory diseases. The company plans to initiate a Phase 2b trial in Crohn’s disease by Q3 2026, with data expected in early 2028. As of June 2026, Shattuck holds $208.3 million in cash, extending its runway into 2029. Additionally, the preclinical pipeline includes SL-846, a dual-targeting antibody set for Phase 1 initiation in mid-2027.
- Shattuck Labs outlined a strategy to develop potentially first-in-class DR3-blocking antibodies for inflammatory and immune-mediated diseases, led by SL-325. * RECEPTIVE-CD1 Phase 2b trial of SL-325 in Crohn’s disease is expected to start in Q3 2026; 12-week induction data targeted for 1H 2028. * Cash and equivalents and short-term investments totaled USD 208.3 million as of June 30, 2026; runway expected into 2029. * Phase 1 program in healthy participants completed; SL-325 reported 3.7% anti-drug antibody rate; estimated half-life 16 days. * Preclinical pipeline includes SL-846, a DR3 x IL-23 receptor antibody with Phase 1 initiation expected in 1H 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shattuck Labs Inc. published the original content used to generate this news brief on August 11, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here